한글목차

두필루맙(Dupixent)은 인터루킨(IL)-4 수용체의 알파 사슬을 표적으로 하는 단클론 항체로, TH2 반응의 주요 촉진제인 사이토카인 IL-4와 IL-13의 생물학적 작용을 억제합니다.

두필루맙은 미국에서 12세 이상의 중등도에서 중증의 아토피피부염(AD) 환자 중 피부(외용) 처방 요법으로 잘 조절되지 않거나 외용 요법을 사용할 수 없는 환자를 치료하기 위해 승인되었습니다. 은 성인의 감독 하에 투여하는 것이 권장됩니다.

현재 승인된 적응증 외에도 리제네론과 사노피는 두필루맙을 땅콩 알레르기, 벼과 식물 알레르기와 같은 알레르기성 염증 및 기타 제2형 염증으로 인한 질환에 대한 광범위한 임상 개발 프로그램에서 두필루맙을 검토하고 있습니다. 소아 AD, 소아 천식, 호산구성 식도염, 만성폐쇄성폐질환(COPD), 수포성 천포창, 결절성 소양증, 만성 자연 두드러기, 알레르기성 기관지폐 아스페르길루스증 등을 대상으로 하고 있습니다.

주요 7개국의 두필루맙 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 수포성류천포창에 대한 두필루맙의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 두필루맙 시장 평가

• 수포성류천포창에 대한 두필루맙의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 수포성류천포창에 대한 두필루맙의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"Dupilumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about dupilumab for bullous pemphigoid in the seven major markets. A detailed picture of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dupilumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dupilumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid.

Drug Summary:

Dupilumab (Dupixent) is a monoclonal antibody targeting the α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response (Sastre, 2018).

Dupilumab is approved in the US to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. In adolescents 12 years of age or older, it is recommended that dupilumab be administered by or under an adult's supervision.

In addition to the currently approved indications, Regeneron and Sanofi are also investigating dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including peanut allergy, grass allergy, AD in pediatric patients, asthma in pediatric patients, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), prurigo nodularis, chronic spontaneous urticaria, and allergic bronchopulmonary aspergillosis.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the dupilumab description, mechanism of action, dosage and administration, research and development activities in bullous pemphigoid.
• Elaborated details on dupilumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the dupilumab research and development activities in bullous pemphigoid across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around dupilumab.
• The report contains forecasted sales of dupilumab for bullous pemphigoid till 2032.
• Comprehensive coverage of the late-stage emerging therapies for bullous pemphigoid.
• The report also features the SWOT analysis with analyst views for dupilumab in bullous pemphigoid.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dupilumab Analytical Perspective by DelveInsight

• In-depth Dupilumab Market Assessment

This report provides a detailed market assessment of dupilumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Dupilumab Clinical Assessment

The report provides the clinical trials information of dupilumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for bullous pemphigoid is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence dupilumab dominance.
• Other emerging products for bullous pemphigoid are expected to give tough market competition to dupilumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of dupilumab in bullous pemphigoid.
• Our in-depth analysis of the forecasted sales data of dupilumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the dupilumab in bullous pemphigoid.

Key Questions

• What is the product type, route of administration and mechanism of action of dupilumab?
• What is the clinical trial status of the study related to dupilumab in bullous pemphigoid and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the dupilumab development?
• What are the key designations that have been granted to dupilumab for bullous pemphigoid?
• What is the forecasted market scenario of dupilumab for bullous pemphigoid?
• What are the forecasted sales of dupilumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to dupilumab for bullous pemphigoid?
• Which are the late-stage emerging therapies under development for the treatment of bullous pemphigoid?

Table of Contents

1. Report Introduction

2. Dupilumab Overview in bullous pemphigoid

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Dupilumab Market Assessment

• 5.1. Market Outlook of Dupilumab in bullous pemphigoid
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Dupilumab in the 7MM for bullous pemphigoid
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Dupilumab in the United States for bullous pemphigoid
  • 5.3.2. Market Size of Dupilumab in Germany for bullous pemphigoid
  • 5.3.3. Market Size of Dupilumab in France for bullous pemphigoid
  • 5.3.4. Market Size of Dupilumab in Italy for bullous pemphigoid
  • 5.3.5. Market Size of Dupilumab in Spain for bullous pemphigoid
  • 5.3.6. Market Size of Dupilumab in the United Kingdom for bullous pemphigoid
  • 5.3.7. Market Size of Dupilumab in Japan for bullous pemphigoid

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options